近年来，胰高血糖素样肽-1（GLP-1）受体激动剂被广泛用于肥胖治疗，并取得了良好的效果。 Survodutide是一种新型的胰高血糖素受体（GCGR）和胰高血糖素样肽-1受体（GLP-1R）双靶激动剂 ...

Researchers have proposed combining GCGR agonists with insulinotropic agents ... of weight loss and blood sugar control on Type 2 diabetes Revolutionary new diabetes drug multiplies insulin ...

By providing three robust platforms to study GLP-1R, GIPR, and GCGR mediated therapies, INDIGO can help researchers accelerate their development of dual- or triple-agonist therapies for diabetes ...

Additionally, by activating the GCGR, Retatrutide may influence glucose ... It has been theorized that these peptides might offer new approaches in diabetes and obesity-related research, which ...